Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer

Proteomics - Clinical Applications

Volumn 5, Issue 9-10, 2011, Pages 493-503

  Bryan, Richard T ^a   Wei, Wenbin ^a   Shimwell, Neil J ^a   Collins, Stuart I ^a   Hussain, Syed A ^a   Billingham, Lucinda J ^a   Murray, Paul G ^a   Deshmukh, Nayneeta ^b   James, Nicholas D ^a   Wallace, D Michael A ^c   Johnson, Philip J ^a   Zeegers, Maurice P ^a   Cheng, K K ^a   Martin, Ashley ^a   Ward, Douglas G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c FREMANTLE HOSPITAL   (Australia)

Author keywords

Biomarker; Bladder; Cancer; Peptidome; Urine

Indexed keywords

ALANYLALANYLHISTIDYLLEUCYLPROLYLALANYLGLUTAMYLPHENYLALANYLTHREONYLPROLYLALANYLVALYLHISTIDYLALANYLSERYLLEUCYLASPARTYLLYSLPHENYLALANYLLEUCYLALANYLSERYLVALYLSERINE; ALBUMIN; ASPARTYLALANYLHISTIDYLLYSLSERYLGLUTAMYLVALYLALANYLHISTIDYLARGINYLPHENYLALANYLLYSYLASPARTYLLEUCYLGLYCYLGLUTAMYLGLUTAMYLASPARAGINYLPHENYLALANYLLYSLALANYLLEUCYLVALYLLEUCINE; ASPARTYLALANYLHISTIDYLLYSYLSERYLGLUTAMYLVALYLALANYLHISTIDYLARGINYLPHENYLALANYLLYSYLASPARTYLLEUCYLGLYCYLGLUTAMYLGLUTAMYLASPARAGINYLPHENYLALANYLLYSYLALANINE; BIOLOGICAL MARKER; GLYCYLTHREONYLLEUCYLSERYLGLYCYLISOLEUCYLGLYCYLTHREONYLLEUCYLASPARTYLGLYCYLPHENYLALANYLARGINYLHISTIDYLARGINYLHISTIDYLPROLYLASPARTYLGLUTAMYLALANYLALANYLPHENYLALANINE; LEUCYLVALYLARGINYLTYROSYLTHREONYLLYSYLLYSYLVALYLPROLYLGLUTAMYLVALYLSERYLTHREONYLPROLYLTHREONINE; POLYPEPTIDE; TYROSYLSERYLMETHIONYLARGINYLLYSYLMETHIONYLSERYLMETHIONYLLYSYLISOLEUCYLARGINYLPROLYLPHENYLALANYLPHENYLALANYLPROLYLGLUTAMYLGLUTAMINE; UNCLASSIFIED DRUG; VALYLARGINYLTYROSYLTHREONYLLYSYLLYSYLVALYLPROLYLGLUTAMYLVALYLSERYLTHREONYLPROLYLTHREONYLLEUCINE;

ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FALSE POSITIVE RESULT; HEMATURIA; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; REPRODUCIBILITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PEPTIDES; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80053647484     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100011     Document Type: Article

References (43)

1. Aben, K., Kiemeney, L., Epidemiology of bladder cancer. Eur. Urol. 1999, 36, 660-672.
2. Babjuk, M., Oosterlinck, W., Sylvester, R., Kaaisnen, E., Bohle, A. et al., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008, 54, 303-314.
3. Stenzl, A., Cowan, N., De Santis, M., Jakse, G. et al., The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 2009, 55, 815-825.
4. Stein, J., Lieskovsky, G., Cote, R., Groshen, S. et al., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 2001, 19, 666-675.
5. Birkhahn, M., Mitra, A. P., Williams, A. J., Lam, G. et al., Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur. Urol. 2010, 57, 12-20.
6. Stenzl, A., Hennenlotter, J., Schilling, D., Can we still afford bladder cancer? Curr. Opin. Urol. 2008, 18, 488-492.
7. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., Hauser, R., The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21, 1315-1330.
8. Hong, Y. M., Loughlin, K. R., Economic impact of tumor markers in bladder cancer surveillance. Urology 2008, 71, 131-135.
9. Gaston, K. E., Grossman, H. B., Proteomic assays for the detection of urothelial cancer. Methods Mol. Biol. 2010, 641, 303-323.
10. Herman, M. P., Svatek, R. S., Lotan, Y., Karakiewizc, P. I., Shariat, S. F., Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol. Nefrol. 2008, 60, 217-235.
11. Lintula, S., Hotakainen, K., Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Exp. Opin. Biol. Ther. 2010, 10, 1169-1180.
12. Bryan, R., Zeegers, M., James, N., Wallace, D., Cheng, K., Biomarkers in bladder cancer. BJU Int. 2009, 105, 608-613.
13. Barboro, P., Rubagotti, A., Orecchia, P., Spina, B. et al., Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol. 2008, 30, 13-26.
14. Getzenberg, R., Konety, B., Oeler, T., Quigley, M. et al., Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996, 56, 1690-1694.
15. Tolson, J., Flad, T., Gnau, V., Dihazi, H. et al., Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6, 697-708.
16. Lin, C., Tsui, K., Yu, C., Yeh, C. et al., Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 2006, 6, 4381-4389.
17. Makridakis, M., Roubelakis, M., Bitsika, V., Dimuccio, V. et al., Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J. Proteome Res. 2010, 9, 3243-3259.
18. Minami, S., Sato, Y., Matsumoto, T., Kageyama, T., Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics 2010, 7, 181-189.
19. Schwamborn, K., Krieg, R., Grosse, J., Reulen, N. et al., Serum proteomic profiling in patients with bladder cancer. Eur. Urol. 2009, 56, 989-997.
20. Irmak, S., Tilki, D., Heukeshoven, J., Oliveira-Ferrer, L. et al., Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5, 4296-4304.
21. Kreunin, P., Zhao, J., Rosser, C., Urquidi, V. et al., Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 2007, 6, 2631-2639.
22. Orenes-Piñero, E., Cortón, M., González-Peramato, P., Algaba, F. et al., Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J. Proteome Res. 2007, 11, 4440-4448.
23. Smalley, D., Sheman, N., Nelson, K., Theodorescu, D., Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J. Proteome Res. 2008, 7, 2088-2096.
24. Munro, N., Cairns, D., Clarke, P., Rogers, M. et al., Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer 2006, 119, 2642-2650.
25. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K. et al., Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
26. Zhang, Y., Wu, D., Guan, M., Liu, W. et al., Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 2004, 37, 772-779.
27. Schiffer, E., Vlahou, A., Petrolekas, A., Stravodimos, K. et al., Prediction of muscle-invasive bladder cancer using urinary proteomics. 2009, 15, 4935-4943.
28. Theodorescu, D., Wittke, S., Ross, M., Walden, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006, 7, 230-240.
29. Neuhoff, N., Kaiser, T., Wittke, S., Krebs, R. et al., Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 18, 149-156.
30. Bosso, N., Chinello, C., Picozzi, S. C., Gianazza, E. et al., Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin. Appl. 2008, 2, 1036-1046.
31. Hortin, G., Meilinger, B., Drake, S., Size-selective extraction of peptides from urine for mass spectrometric analysis. Clin. Chem. 2004, 50, 1092-1095.
32. Terracciano, R., Pasqua, L., Casadonte, F., Frascà, S. et al., Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Bioconjug. Chem. 2009, 20, 913-923.
33. Lapolla, A., Molin, L., Sechi, A., Cosma, C. et al., A further investigation on a MALDI-based method for evaluation of markers of renal damage. J. Mass Spectrom. 2009, 44, 1754-1760.
34. Zeegers, M. P., Bryan, R. T., Langford, C., Billingham, L. et al., The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int. 2010, 105, 784-788.
35. Zeegers, M., Bryan, R., Langford, C., Billingham, L. et al., The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int. 2010, 105, 784-788.
36. Siwy, J., Mullen, W., Golovko, I., Franke, J. et al., Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin. Appl. 2011, 5, 367-374.
37. Abd, E. l., Gawad, I., Moussa, H., Nasr, M. et al., Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J. Egypt Natl. Canc. Inst. 2005, 17, 193-202.
38. DeLong, E., DeLong, D., Clarke-Pearson, D., Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics 1988, 44, 837-845.
39. Gay, S., Binz, P. A., Hochstrasser, D. F., Appel, R. D., Modeling peptide mass fingerprinting data using the atomic composition of peptides. Electrophoresis 1999, 20, 3527-3534.
40. Maahs, D. M., Siwy, J., Argilés, A., Cerna, M. et al., Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One 2010, 5, e13051.
41. Skipworth, R. J., Stewart, G. D., Bhana, M., Christie, J. et al., Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int. J. Oncol. 2010, 36, 973-982.
42. Sanchez-Carbayo, M., Socci, N., Lozano, J., Haab, B., Cordon-Cardo, C., Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168, 93-103.
43. Diamandis, E., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3, 367-378.